Payment overview · 2025
General Payments
$2,309.50
122 reported records · 16 companies
Healthcare provider profile · identity verified
Isaac B. Tunnell, P.A.
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · LAS VEGAS, NV · NPI 1164670634
Verified facts
What the public records show
CMS Open Payments records show Isaac B. Tunnell, P.A. received $2,309.50 in general payments during 2025 across 122 reported records.
Collegium Pharmaceutical, Inc. accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Belbuca, Horizant, Nucynta, Ztlido.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HORIZANT as an associated drug or biological on 2733 records involving 1696 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Horizant by this doctor in 2024.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BELBUCA as an associated drug or biological on 17475 records involving 4385 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Belbuca by this doctor in 2024.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nucynta as an associated drug or biological on 230 records involving 95 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Nucynta by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ztlido by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $470.61 | 20.4% | 30 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $340.49 | 14.7% | 21 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $314.95 | 13.6% | 14 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $303.95 | 13.2% | 16 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $253.78 | 11.0% | 13 | 2025 |
| Orexo US, Inc. | Unresolved — no canonical attribution shown | $155.59 | 6.7% | 7 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $135.87 | 5.9% | 6 | 2025 |
| Forte Bio-Pharma LLC | Unresolved — no canonical attribution shown | $90.45 | 3.9% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $58.95 | 2.5% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.09 | 1.6% | 2 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $36.00 | 1.6% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $26.83 | 1.2% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $24.35 | 1.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $24.34 | 1.1% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $20.15 | 0.9% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $15.10 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,309.50 | 122 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $314.95 | 14 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $314.37 | 20 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $305.38 | 19 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $303.95 | 16 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $255.51 | 15 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $253.78 | 13 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $253.78 | 13 | 2025 |
Source payment records
|
|||||
| Nucynta Normalized: nucynta |
Drug | Collegium Pharmaceutical, Inc. | $178.46 | 12 | 2025 |
Source payment records
|
|||||
| Zubsolv Normalized: zubsolv |
Drug | Orexo US, Inc. | $155.59 | 7 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $135.87 | 6 | 2025 |
Source payment records
|
|||||
| NALOCET Normalized: nalocet |
Drug | Forte Bio-Pharma LLC | $90.45 | 4 | 2025 |
Source payment records
|
|||||
| PROLATE Normalized: prolate |
Drug | Forte Bio-Pharma LLC | $90.45 | 4 | 2025 |
Source payment records
|
|||||
| TANLOR Normalized: tanlor |
Drug | Forte Bio-Pharma LLC | $90.45 | 4 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $58.95 | 2 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $38.09 | 2 | 2025 |
Source payment records
|
|||||
| XTAMPZA Normalized: xtampza |
Drug | Collegium Pharmaceutical, Inc. | $36.64 | 3 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $36.00 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $26.83 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $15.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Belbuca belbuca |
2025 | Belbuca | 2024 | 90 | exact normalized | Medicare Part D |
| HORIZANT horizant |
2025 | Horizant | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Nucynta nucynta |
2025 | Nucynta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | HORIZANT open payments reported associated product |
CMS Open Payments — General Payments 2733 supporting records · 1696 recipient NPIs · example record 1242666828 |
Horizant · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | BELBUCA open payments reported associated product |
CMS Open Payments — General Payments 17475 supporting records · 4385 recipient NPIs · example record 1224105020 |
Belbuca · 2024 Exact normalized brand match · 1 Part D row |
90 | 15 |
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | Nucynta open payments reported associated product |
CMS Open Payments — General Payments 230 supporting records · 95 recipient NPIs · example record 1224105108 |
Nucynta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 440 | 93 |
| Tizanidine Hcl | Tizanidine Hcl | 435 | 100 |
| Morphine Sulfate Er | Morphine Sulfate | 384 | 59 |
| Morphine Sulfate | Morphine Sulfate | 372 | 56 |
| Celecoxib | Celecoxib | 368 | 102 |
| Tramadol Hcl | Tramadol Hcl | 362 | 71 |
| Tramadol Hcl Er | Tramadol Hcl | 301 | 57 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 205 | 29 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 165 | 42 |
| Pregabalin | Pregabalin | 151 | 32 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 135 | 22 |
| Methocarbamol | Methocarbamol | 103 | 24 |
| Methadone Hcl | Methadone Hcl | 91 | 19 |
| Belbuca | Buprenorphine Hcl | 90 | 15 |
| Meloxicam | Meloxicam | 66 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 12 |
| Fentanyl | Fentanyl | 62 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 55 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 55 | 13 |
| Lidocaine | Lidocaine | 54 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 20 |
| Baclofen | Baclofen | 46 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 44 | suppressed |
| Buprenorphine | Buprenorphine | 43 | 11 |
| Naloxone Hcl | Naloxone Hcl | 41 | 39 |
| Buprenorphine Hcl | Buprenorphine Hcl | 36 | suppressed |
| Ibuprofen | Ibuprofen | 35 | 11 |
| Dayvigo | Lemborexant | 30 | suppressed |
| Nucynta Er | Tapentadol Hcl | 28 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 26 | suppressed |
| Nucynta | Tapentadol Hcl | 25 | suppressed |
| Sulfasalazine | Sulfasalazine | 25 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Butrans | Buprenorphine | 20 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Belsomra | Suvorexant | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 14 |
| Ztlido | Lidocaine | 16 | suppressed |
| Horizant | Gabapentin Enacarbil | 15 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Metaxalone | Metaxalone | 12 | suppressed |
| Sprix | Ketorolac Tromethamine | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,309.50 · 122 records | Collegium Pharmaceutical, Inc. | BRIXADI, Belbuca, Flector, General - Pain Management, HORIZANT, Licart, NALOCET, NURTEC ODT, Nucynta, PROLATE, QULIPTA, QUTENZA, Quviviq, RELISTOR, SUBLOCADE, Sunosi, TANLOR, Tirosint, UBRELVY, VYEPTI, XTAMPZA, ZAVZPRET, ZTLido, Zubsolv | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Belbuca play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Azurity Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error